Profile data is unavailable for this security.
About the company
Abpro Holdings, Inc. is a biotechnology company dedicated to developing next-generation antibody therapeutics, which helps in improving the lives of patients with severe and life-threatening diseases. The Company is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its DiversImmune and MultiMab antibody discovery and engineering platforms, it is engaged in developing a pipeline of antibodies, both independently and through collaborations with global pharmaceutical and research institutions. Its two lead product candidates, ABP-102 and ABP-201, feature its next generation tetravalent antibody format (TetraBi antibody format), which binds to two different targets with two distinct binding sites per target. ABP-102 is designed to redirect a patient’s immune system to fight cancer by engaging T cells through co-targeting human epidermal growth factor receptor 2 (HER2), and cluster of differentiation 3 (CD3), T-cell co-receptor.
- Revenue in USD (TTM)0.00
- Net income in USD4.29m
- Incorporated2021
- Employees--
- LocationABPRO Holdings Inc6 St Johns Lane, Floor 5NEW YORK 10013United StatesUSA
- Phone+1 (248) 890-7200
- Fax+1 (302) 655-5049
- Websitehttps://atlantic-coastal.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tempest Therapeutics Inc | 0.00 | -35.52m | 22.83m | 17.00 | -- | 2.10 | -- | -- | -1.57 | -1.57 | 0.00 | 0.4313 | 0.00 | -- | -- | 0.00 | -122.85 | -57.10 | -195.00 | -71.20 | -- | -- | -- | -- | -- | -- | 0.426 | -- | -- | -- | 17.41 | -- | 36.40 | -- |
| Forte Biosciences Inc | 0.00 | -34.20m | 23.36m | 11.00 | -- | 2.49 | -- | -- | -20.00 | -20.00 | 0.00 | 6.42 | 0.00 | -- | -- | 0.00 | -103.90 | -72.06 | -137.40 | -82.27 | -- | -- | -- | -491,850.00 | -- | -- | 0.00 | -- | -- | -- | -126.79 | -- | -46.29 | -- |
| Lisata Therapeutics Inc | 0.00 | -20.74m | 23.96m | 25.00 | -- | 0.7112 | -- | -- | -2.51 | -2.51 | 0.00 | 4.05 | 0.00 | -- | -- | 0.00 | -43.08 | -45.97 | -47.69 | -50.47 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 61.57 | -- | -- | -- |
| Ibio Inc | 175.00k | -14.36m | 24.12m | 16.00 | -- | 1.28 | -- | 137.85 | -3.97 | -6.65 | 0.0307 | 2.06 | 0.0056 | -- | -- | 10,937.50 | -46.17 | -27.69 | -75.53 | -33.13 | -- | -- | -8,204.57 | -1,862.11 | -- | -- | 0.0736 | -- | -- | -35.52 | 47.31 | -- | -26.66 | -- |
| Athira Pharma Inc | 0.00 | -109.22m | 24.68m | 65.00 | -- | 0.4311 | -- | -- | -2.85 | -2.85 | 0.00 | 1.49 | 0.00 | -- | -- | 0.00 | -80.62 | -30.73 | -101.80 | -32.46 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.04 | -- | -- | -- |
| Cadrenal Therapeutics Inc | 0.00 | -7.61m | 24.86m | 4.00 | -- | 5.42 | -- | -- | -7.05 | -7.05 | 0.00 | 2.76 | 0.00 | -- | -- | 0.00 | -108.76 | -- | -125.13 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.47 | -- | -- | -- |
| Cell Source Inc | 0.00 | -6.57m | 24.88m | -- | -- | -- | -- | -- | -0.1613 | -0.1613 | 0.00 | -0.4379 | 0.00 | -- | -- | -- | -2,039.39 | -1,758.85 | -- | -- | -- | -- | -- | -- | -- | -3.74 | -- | -- | -- | -- | -3.55 | -- | -- | -- |
| Ocean Biomedical Inc | 0.00 | -98.59m | 24.95m | 9.00 | -- | -- | -- | -- | -3.01 | -3.01 | 0.00 | -2.21 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -0.2443 | -- | -- | -- | -- | 72.16 | -- | -- | -- |
| ABPRO Holdings Inc | 0.00 | 4.29m | 24.97m | -- | 22.25 | 1.58 | -- | -- | 0.1396 | 0.1396 | 0.00 | 1.97 | 0.00 | -- | -- | -- | 2.48 | -- | 2.53 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 49,648.60 | -- | -- | -- |
| Equillium Inc | 45.91m | -4.62m | 25.19m | 45.00 | -- | 1.09 | -- | 0.5486 | -0.1316 | -0.1316 | 1.29 | 0.6543 | 1.02 | -- | 10.46 | 1,043,500.00 | -10.29 | -46.81 | -18.30 | -57.36 | -- | -- | -10.05 | -328.35 | -- | -- | 0.00 | -- | 128.97 | -- | 78.64 | -- | 7.48 | -- |
| Citius Pharmaceuticals Inc | 0.00 | -39.77m | 25.85m | 22.00 | -- | 0.2822 | -- | -- | -0.2443 | -0.2443 | 0.00 | 0.4741 | 0.00 | -- | -- | 0.00 | -36.91 | -30.26 | -39.00 | -32.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.1589 | -- | -- | -- |
| Hookipa Pharma Inc | 50.00m | -43.37m | 25.92m | 151.00 | -- | 0.361 | -- | 0.5184 | -4.11 | -4.11 | 4.24 | 5.96 | 0.3653 | -- | 100.10 | 331,119.20 | -31.69 | -41.63 | -42.40 | -50.26 | -- | -- | -86.74 | -366.65 | -- | -- | 0.00 | -- | 41.27 | 21.41 | -25.67 | -- | 14.11 | -- |
| Eterna Therapeutics Inc | 598.00k | -44.95m | 26.71m | 8.00 | -- | -- | -- | 44.67 | -8.31 | -8.31 | 0.1105 | -8.39 | 0.0199 | -- | 0.6093 | 74,750.00 | -149.86 | -169.05 | -222.51 | -223.00 | 72.91 | -- | -7,513.88 | -682.61 | -- | -5.43 | -- | -- | -- | -68.89 | 11.84 | -- | -58.86 | -- |
| Mink Therapeutics Inc | 0.00 | -13.78m | 26.89m | 31.00 | -- | -- | -- | -- | -0.3865 | -0.3865 | 0.00 | -0.4439 | 0.00 | -- | -- | 0.00 | -185.76 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 19.77 | -- | -- | -- |
